Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
10.35
+0.37 (3.71%)
At close: Oct 15, 2026, 4:00 PM EDT
10.15
-0.20 (-1.93%)
After-hours: Oct 15, 2026, 7:30 PM EDT
Fennec Pharmaceuticals Market Cap
Fennec Pharmaceuticals has a market cap or net worth of $362.95 million as of October 15, 2026. It is the 16,951st most valuable company in the world and the 3,006th biggest in the United States. Its market cap has increased by 57.60% in one year.
Market Cap
362.95M
Enterprise Value
321.70M
1-Year Change
57.60%
Global Rank
Country Rank
#3,006 United States
Category
ChartMarket Cap Chart
Since December 31, 2004, Fennec Pharmaceuticals's market cap has increased from $65.80M to $362.95M, an increase of 451.59%. That is a compound annual growth rate of 8.15%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 15, 2026 | 362.95M | 67.64% |
| Dec 31, 2025 | 216.50M | 24.86% |
| Dec 31, 2024 | 173.40M | -41.97% |
| Dec 29, 2023 | 298.80M | 18.62% |
| Dec 30, 2022 | 251.90M | 120.19% |
| Dec 31, 2021 | 114.40M | -40.51% |
| Dec 31, 2020 | 192.30M | 48.95% |
| Dec 31, 2019 | 129.10M | 2.54% |
| Dec 31, 2018 | 125.90M | -20.82% |
| Dec 29, 2017 | 159.00M | 444.52% |
| Dec 30, 2016 | 29.20M | 53.68% |
| Dec 31, 2015 | 19.00M | -28.30% |
| Dec 31, 2014 | 26.50M | 208.14% |
| Dec 31, 2013 | 8.60M | -34.35% |
| Dec 31, 2012 | 13.10M | 61.73% |
| Dec 30, 2011 | 8.10M | -55.98% |
| Dec 31, 2010 | 18.40M | 260.78% |
| Dec 31, 2009 | 5.10M | - |
| Dec 31, 2008 | 5.10M | -85.26% |
| Dec 31, 2007 | 34.60M | 138.62% |
| Dec 29, 2006 | 14.50M | -51.67% |
| Dec 30, 2005 | 30.00M | -54.41% |
| Dec 31, 2004 | 65.80M | - |
| Dec 31, 2004 | 65.80M | - |
View and export this data all the way back to 2004. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Galectin Therapeutics | 372.14M |
| Prelude Therapeutics | 366.66M |
| Eikon Therapeutics | 363.99M |
| Scribe Therapeutics | 361.97M |
| Relmada Therapeutics | 358.41M |
| Kyverna Therapeutics | 356.84M |
| Opus Genetics | 352.75M |
| vTv Therapeutics | 350.75M |